Philippe Wolgen
Chief Executive Officer chez CLINUVEL PHARMACEUTICALS LIMITED
Fortune : 32 M $ au 31/03/2024
Profil
Philippe Jacques Wolgen is currently the Chief Executive Officer, MD & Director at Clinuvel Pharmaceuticals Ltd.
and also serves as a Director at Clinuvel (UK) Ltd.
He holds an MBA from The Trustees of Columbia University in The City of New York and London Business School, and a doctorate from the University of Utrecht.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
24/11/2023 | 3 425 222 ( 6,83% ) | 32 M $ | 31/03/2024 |
Postes actifs de Philippe Wolgen
Sociétés | Poste | Début |
---|---|---|
CLINUVEL PHARMACEUTICALS LIMITED | Chief Executive Officer | 01/11/2005 |
Clinuvel (UK) Ltd.
Clinuvel (UK) Ltd. BiotechnologyHealth Technology Part of Clinuvel Pharmaceuticals Ltd., Clinuvel (UK) Ltd. is a British company founded in 2005 that provides research and development in the field of biotechnology. The private company is based in London, UK. | Director/Board Member | 25/11/2005 |
Formation de Philippe Wolgen
The Trustees of Columbia University in The City of New York | Masters Business Admin |
University of Utrecht | Doctorate Degree |
London Business School | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
CLINUVEL PHARMACEUTICALS LIMITED | Health Technology |
Entreprise privées | 1 |
---|---|
Clinuvel (UK) Ltd.
Clinuvel (UK) Ltd. BiotechnologyHealth Technology Part of Clinuvel Pharmaceuticals Ltd., Clinuvel (UK) Ltd. is a British company founded in 2005 that provides research and development in the field of biotechnology. The private company is based in London, UK. | Health Technology |